STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF

rhuMAb VEGF是一种实验性人源化单克隆抗体， 基因泰克使用重组DNA技术。 抗体是蛋白质， 可以保护身体免受外来入侵者，如细菌和病毒。 rhuMAb VEGF是血管内皮生长因子的单克隆抗体 血管内皮生长因子（VEGF），其存在于多种正常组织中，但 大多数实体癌（肿瘤）过量产生>在 在癌症中，VEGF促进血管的生长， 肿瘤细胞。 在实验室研究中，rhuMAb VEGF抑制了 通过阻断VEGF的作用来治疗动物的许多不同的癌症。

rhuMAb VEGF is an experimental humanized monoclonal antibody produced by Genentech using recombinant DNA technology. Antibodies are proteins that can protect the body from foreign invaders, such as bacteria and viruses. rhuMAb VEGF is a monoclonal antibody to vascular endothelial growth factor (VEGF), which is present in a wide variety of normal tissues but is produced in excess by most solid cancers (tumors)> In the setting of cancer, VEGF promotes the growth of blood vessels that bring nutrients to the tumor cells. In laboratory studies, rhuMAb VEGF inhibits the growth of many different cancers in animals by blocking the effects of VEGF.